Cargando…

Determinants of mTOR inhibitor therapy in AIDS-associated malignancies

Detalles Bibliográficos
Autores principales:	Dittmer, Dirk P, Damania, Blossom, Sin, Sang-Hoon, Roy, Debasmita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330046/ http://dx.doi.org/10.1186/1750-9378-7-S1-O9

Ejemplares similares

Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
por: Rivera-Soto, Ricardo, et al.
Publicado: (2021)

Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Caro-Vegas, Carolina, et al.
Publicado: (2019)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The phosphatidylinositol-3 kinase/mTOR pathway: new agents
por: Arteaga, CL
Publicado: (2011)

Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
por: Bhatt, A, et al.
Publicado: (2009)

Hsp90 Inhibitors Are Efficacious against Kaposi Sarcoma by Enhancing the Degradation of the Essential Viral Gene LANA, of the Viral Co-Receptor EphA2 as well as Other Client Proteins
por: Chen, Wuguo, et al.
Publicado: (2012)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Profiling of cellular and viral microRNAs in Kaposi sarcoma and viral-associated lymphoma
por: Dittmer, DP, et al.
Publicado: (2009)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Development and evolution of the MHAUS cognitive aid for malignant hyperthermia
por: Pinyavat, Teeda, et al.
Publicado: (2014)

Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human
por: Eason, Anthony B., et al.
Publicado: (2016)

Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated Malignancies
por: Chugh, Pauline E., et al.
Publicado: (2013)

HIV/AIDS and health services: misaligned policy and maligned subjects
por: Amin, Aalya, et al.
Publicado: (2012)

The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy
por: Geissler, Edward K
Publicado: (2013)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

mTOR Regulation of Metabolism in Hematologic Malignancies
por: Mirabilii, Simone, et al.
Publicado: (2020)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

MCT4 is an important determinant for the growth of highly glycolytic and aggressive malignancies
por: Unsal-Kacmaz, Kezi, et al.
Publicado: (2012)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

Treatment of Kaposi Sarcoma-Associated Herpesvirus-Associated Cancers
por: Dittmer, Dirk P., et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

A scientific basis to determine the best paliative treatment for malignant pleural effusion
por: Hojski, A, et al.
Publicado: (2013)

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment
por: Heinzen, Dennis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_it61c2umuu63m2cje699nifff4